Interferon β for Multiple Sclerosis

Dejan Jakimovski

doi:10.1101/cshperspect.a032003

2018-01-08

109

Weinstock-Guttman, Bianca *

DOI：10.1101/cshperspect.a032003

原文链接

查看原文

摘要

En 中文

Despite that the availability of new therapeutic options has expanded the multiple sclerosis (MS) disease-modifying therapy arsenal, interferon beta (IFN-beta) remains an important therapy option in the current decision-making process. This review will summarize the present knowledge of IFN-beta mechanism of action, the overall safety, and the short- and long-term efficacy of its use in relapsing remitting MS and clinically isolated syndromes. Data on secondary progressive MS is also provided, although no clear benefit was identified.

Keyword:

TERM-FOLLOW-UP

DISEASE-MODIFYING THERAPIES

RANDOMIZED CONTROLLED-TRIAL

EUROPEAN MULTICENTER TRIAL

SECONDARY PROGRESSIVE MS

BRAIN VOLUME CHANGES

INTRAMUSCULAR INTERFERON

NEUTRALIZING ANTIBODIES

DOUBLE-BLIND

IFN-BETA

AI总结

对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。

期刊

Cold Spring Harbor Perspectives in Medicine

IF:

10.1

论文数:

3.0K

被引数:

1.3W

机构

state university of new york (suny) system

学者数:

6.5W

论文数: 5.8W

被引数: 65

university at buffalo, suny

学者数:

1.2W

论文数: 9.5K

被引数: 9

引用论文

Anti-IFN BAb and NAb antibodies - A minireview

NEUROLOGY

IF8.5

2003-11-11

PREAI

Bendtzen, K

Study on the response of circular thin plate under low velocity impact

Geomechanics and Engineering

IF0

2015-08-25

PREAI

Hashem Babaei; Tohid Mirzababaie Mostofi; Majid Alitavoli

The Borrelia burgdorferi flagellum-associated 41-kilodalton antigen (flagellin): molecular cloning, expression, and amplification of the gene

Infection and Immunity

IF0

1990-06-01

OAAI

R Wallich; S E Moter; M M Simon; K Ebnet; A Heiberger; M D Kramer

Bioequivalence and the immunogenicity of biopharmaceuticals 生物药品的生物等效性和免疫原性

NATURE REVIEWS DRUG DISCOVERY

IF101.8

2002-06-01

484

PREAI

Schellekens, H

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

IF7.5

2013-11-11

OAAI

Edan, G.; Kappos, L.; Montalban, X.; Polman, C. H.; Freedman, M. S.; Hartung, H-P; Miller, D.; Barkhof, F.; Herrmann, J.; Lanius, V.; Stemper, B.; Pohl, C.; Sandbrink, R.; Pleimes, D.

Assessing response to interferon-β in a multicenter dataset of patients with MS

NEUROLOGY

IF8.5

2016-07-12

OAAI

Sormani, Maria Pia; Gasperini, Claudio; Romeo, Marzia; Rio, Jordi; Calabrese, Massimiliano; Cocco, Eleonora; Enzingher, Christian; Fazekas, Franz; Filippi, Massimo; Gallo, Antonio; Kappos, Ludwig; Marrosu, Maria Giovanna; Martinelli, Vittorio; Prosperini, Luca; Rocca, Maria Assunta; Rovira, Alex; Sprenger, Till; Stromillo, Maria Laura; Tedeschi, Gioacchino; Tintore, Mar; Tortorella, Carla; Trojano, Maria; Montalban, Xavier; Pozzilli, Carlo; Comi, Giancarlo; De Stefano, Nicola

Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimer’s Disease

Dementia and Geriatric Cognitive Disorders

IF0

1998-08-19

PREAI

Maria Eriksdotter Jönhagen; Agneta Nordberg; Kaarina Amberla; Lars Bäckman; Ted Ebendal; Björn Meyerson; Lars Olson; Åke Seiger; Masahiro Shigeta; Elvar Theodorsson; Matti Viitanen; Bengt Winblad; Lars-Olof Wahlund

Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial

JOURNAL OF THE NEUROLOGICAL SCIENCES

IF3.2

2005-12-01

PREAI

Panitch, H; Goodin, D; Francis, G; Chang, P; Coyle, P; O'Connor, P; Li, D; Weinshenker, B

Ten-year follow-up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial

MULTIPLE SCLEROSIS JOURNAL

IF5

2014-10-24

PREAI

Simon, J. H.; Kinkel, R. P.; Kollman, C.; O'Connor, P.; Fisher, E.; You, X.; Hyde, R.